Publications & Patents

Publications & Patents

Total 26건 1 페이지
Publications & Patents 목록
No. 제목
26
Publication

JOURNAL OF CLINICAL ONCOLOGY

2021

AbstractPurpose: Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with…

23.04.18 471
25
Publication

LANCET ONCOLOGY

2019

AbstractBackground: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) given EGFR tyrosine kinase inhibitors (TKIs) inevitably become resistant to first-generation or second-generation drugs. We assessed the safety, tolerability, pharmacokineti…

23.04.18 408
24
Publication

ANNALS OF ONCOLOGY

2021

AbstractBackground: Quavonlimab (MK-1308), a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a phase I study.Patients and methods: Dose-escalation (DE) phase: patients with advanced/metastatic solid tumors received a…

23.04.18 375
23
Publication

CANCER DISCOVERY

2020

AbstractEGFR exon 20 insertion driver mutations (Exon20ins) in non-small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR-MET, has shown preclinical activit…

23.04.18 379
22
Publication

JOURNAL OF CLINICAL ONCOLOGY

2017

AbstractPurpose ROS1 rearrangement is a distinct molecular subset of non-small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC. Patients and Methods We enrolled 32 patients with advanced NSC…

23.04.18 373
21
Publication

JOURNAL OF CLINICAL ONCOLOGY

2013

AbstractPurpose: To investigate the frequency and the prognostic role of fibroblast growth factor receptor 1 (FGFR1) amplification in patients with surgically resected squamous cell carcinoma of the lung (SCCL) and the association between smoking and FGFR…

23.04.18 370
20
Publication

JAMA oncology

2020

AbstractImportance: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small c…

23.04.18 365
19
Publication

JOURNAL OF THORACIC ONCOLOGY

2019

AbstractIntroduction: Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreat…

23.04.18 375
18
Publication

LANCET ONCOLOGY

2022

AbstractBackground: Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. In the CITYSCAPE trial, we aimed t…

23.04.18 378
17
Publication

ANNALS OF ONCOLOGY

2017

Abstract Background: We conducted co-clinical trials in patient-derived xenograft (PDX) models to identify predictive biomarkers for the multikinase inhibitor dovitinib in lung squamous cell carcinoma (LSCC).Methods: The PDX01-02 were establishe…

23.04.18 403
16
15
Poster

AACR

2023

 자세한 사항은 PDF 파일 참고 부탁드립니다.Please find the attahed PDF file. 

23.04.18 402
14
13
Poster

AACR

2023

 자세한 사항은 PDF 파일 참고 부탁드립니다.Please find the attahed PDF file. 

23.04.18 569
12

검색